New Delhi: with him Inclusion With Kovovax adding to India’s COVID immunization programme, children aged 12 and above now have an additional vaccine option to choose from. Other covid vaccines available for this age group are Covaxin and Corbevax,
Covovax, developed by American company Novavax and manufactured in India by Serum Institute of India (SII), is a protein-based vaccine developed from the original SARS-CoV-2 strain. It achieves full efficacy against the virus after the administration of two doses via the intramuscular route. This is the second vaccine from the SII stable, after Covishield. Involved in the national immunization program
On Tuesday, SII low Vaccine price increased from Rs 900 per dose to Rs 225 plus GST and tax.
However, like Sputnik V, which was never purchased by the government but is available in private vaccination centres, Kovovax will also be available only in private centres.
According to health officials, there are currently sufficient vaccine stocks available with the states – 19,01,68,140 doses as per a Press Information Bureau (PIB) update on Tuesday – and it is currently unnecessary to add more vaccines to the government’s procurement list. .
According to a statement released last year by the Pune-based vaccine manufacturer, Covovax is the SII version of Novavax’s NVX-CoV2373 Covid vaccine. It was created using Novavax’s recombinant nanoparticle technology, which generates antigen derived from the coronavirus spike protein, and the vaccine’s patented saponin-based matrix to enhance the immune response and stimulate high levels of neutralizing antibodies. -M is formulated with Adjuvant.
The vaccine was approved in March by the Drugs Controller General of India for use in adolescent age groups. The second dose of Covovax is given three weeks after the first dose.
read also, No one can be forced to vaccinate, but policy is not unfair: Supreme Court
92.6% efficacy against forms of anxiety
Announcing the vaccine’s emergency-use authorization in March, Novavax and SII stated that “a phase 2/3, observer-blind, randomized, controlled study is to be conducted in a total of 460 Indian adolescents aged 12 to <18 years." Was conducted for. Safety and immunogenicity of Kovovax".
“The study demonstrated that Kovovax was well tolerated with a reassuring safety profile. In addition, data indicated that Kovovax is immunogenic in adolescents 12 to <18 years of age. Authorization in India also issued refers to Prevention-19 Breakthrough Phase 3 Pediatric Extension NVX-CoV2373 trial in US adolescents aged 12 to <18…”
That test, according to Novavax’s statement, found that the vaccine was well tolerated, safe and immunosuppressive in 12-17 year olds, and showed 82 percent clinical efficacy against the delta variant.
result NVX-CoV2373 test in adults – showing 92.6 percent efficacy against forms of anxiety Posted in New England Journal of Medicine in February.
According to the Kovovax package insert, pain (among 36.4 percent of recipients) and tenderness (11.3 percent) were the most frequent local adverse events. Fever (in 22.5 percent of recipients), headache (18.8 percent), fatigue (14.2 percent), and malaise (9.2 percent) were the most commonly reported adverse events.
Kovovax is contraindicated in people who have hypersensitivity to the active substance or any component of the vaccine.
SII Factsheet on Vaccines couple“Currently, there is a limited amount of data available in individuals with weakened immune systems or who are taking chronic treatments that suppress or inhibit immune responses. People with weakened immune systems due to other diseases or medications may have severe COVID-19. They can get kovovax.”
However, it said, “People with weakened immune systems should be aware of the potential for a reduced immune response to KovoVax, as well as the need to continue to follow all current guidance to protect themselves against Covid-19.” “.
kovovax was Received The emergency-use list from the World Health Organization last December, days before the vaccine received approval from the Drug Controller General of India for use in adults.
(Edited by Polomi Banerjee)
read also, As private sector boosts uptake, officials say healthcare system may not be in COVID mode forever